166 related articles for article (PubMed ID: 27480131)
1. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
3. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
6. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
7. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
8. Updates in chemoprevention research for hereditary gastrointestinal and polyposis syndromes.
Hall MJ
Curr Treat Options Gastroenterol; 2021 Mar; 19(1):30-46. PubMed ID: 34211259
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
Ma H; Brosens LAA; Elias SG; Morsink FHM; Nijman IJ; Hylind LM; Montgomery EA; Offerhaus GJA; Giardiello FM; de Leng WWJ
Sci Rep; 2017 Sep; 7(1):11972. PubMed ID: 28931879
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora.
Zhou L; Zheng L; Xu B; Ye Z; Li D; Wang W
Orphanet J Rare Dis; 2024 Feb; 19(1):88. PubMed ID: 38403687
[TBL] [Abstract][Full Text] [Related]
11. Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Yang L; Wang Y; Hu S; Wang X
Front Oncol; 2023; 13():1281844. PubMed ID: 38033490
[TBL] [Abstract][Full Text] [Related]
12. Progression of duodenal neoplasia to advanced adenoma in patients with familial adenomatous polyposis.
Nakahira H; Takeuchi Y; Shimamoto Y; Ishiguro S; Yunokizaki H; Ezoe Y; Fujisawa F; Ishihara R; Takayama T; Yoshida T; Mutoh M; Ishikawa H
Hered Cancer Clin Pract; 2023 Nov; 21(1):25. PubMed ID: 38012770
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sulindac for lung cancer chemoprevention.
Limburg PJ; Mandrekar SJ; Aubry MC; Ziegler KL; Zhang J; Yi JE; Henry M; Tazelaar HD; Lam S; McWilliams A; Midthun DE; Edell ES; Rickman OB; Mazzone P; Tockman M; Beamis JF; Lamb C; Simoff M; Loprinzi C; Szabo E; Jett J;
Lung Cancer; 2013 Mar; 79(3):254-61. PubMed ID: 23261228
[TBL] [Abstract][Full Text] [Related]
14. Which Drugs are More Effective in Preventing Familial Adenomatous Polyposis Progression Based on Network Meta-Analysis?
Luo P; Shi W; Cheng X; Yang J; Pei G; Dong J
Curr Pharm Des; 2024 May; ():. PubMed ID: 38698755
[TBL] [Abstract][Full Text] [Related]
15. Effect of physical fitness on colorectal tumor development in patients with familial adenomatous polyposis.
Nakamura T; Ishikawa H; Sakai T; Ayabe M; Wakabayashi K; Mutoh M; Matsuura N
Medicine (Baltimore); 2019 Sep; 98(38):e17076. PubMed ID: 31567943
[TBL] [Abstract][Full Text] [Related]
16. Slow progression of periampullary neoplasia in familial adenomatous polyposis.
Moozar KL; Madlensky L; Berk T; Gallinger S
J Gastrointest Surg; 2002; 6(6):831-7; discussion 837. PubMed ID: 12504221
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes.
Kanth P; Hazel MW; Schell JC; Rutter J; Yao R; Mills AP; Delker DA
Fam Cancer; 2024 Apr; ():. PubMed ID: 38609520
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats.
Madka V; Patlolla JMR; Venkatachalam K; Zhang Y; Pathuri G; Stratton N; Lightfoot S; Janakiram NB; Mohammed A; Rao CV
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568816
[TBL] [Abstract][Full Text] [Related]
19. Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
Almendingen K; Larsen LN; Fausa O; Bratlie J; Høstmark AT; Aabakken L
Fam Cancer; 2010 Dec; 9(4):571-80. PubMed ID: 20593240
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
